News

Eleonora Lad, MD, PhD, spoke about her presentation, "Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of geographic atrophy in dry age-related macular degeneration" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

Nathan Steinle, MD, spoke about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.

Researchers note work may lead to targets for conventional outflow pathway therapies.

Alan Franklin, MD, PhD, FASRS, spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results.

Ashkan Abbey, MD, spoke about his presentation on the CALM registry study, the 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

Therapeutics can prevent vision loss and neurodegeneration in patients.

Sally S. Ong, MD, spoke about her study on the impact of individual and neighborhood-level social determinants of health on vision and foveal status at presentation in patients with rhegmatogenous retinal detachments at the annual ASRS meeting in Stockholm, Sweden.

According to the company, its implantable miniature telescope is a Galilean intraocular telescope designed to improve visual acuity and quality of life for patients with late-stage AMD.

The collaboration agreement will allow the 2 companies to find a potential new treatment for chronic dry eye disease.

John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.

Funding for the device was thanks to companies like Nike and the Oregon ToughTech Breakthrough Fund.

Early diagnosis of NMOSD is key to preventing disability, improving survival.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting.

A recent study found that adolescents with myopia were twice as likely to develop anxiety and mood disorders.

Patrick C. Staropoli, MD, discussed his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa while attending the annual ASRS meeting in Stockholm, Sweden.

The nOCT allows for detailed visualization of the brain's vascular anatomy.

TFI employs spectral interference technology to image and map the corneal surface.

Riaz Qureshi, PhD, explains the effects of spin sneaking into systematic reviews and ways the scientific community can better identify it to improve the validity.

Stephen Russell, MD, discussed his presentation on safety and durability of voretigene neparvovec-rzyl for biallelic RPE65 at the annual ASRS meeting in Stockholm, Sweden.

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

The professor was recently given the award for his contributions to advancing vitreoretinal surgery, treatment, research, and patient care.

Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.